Compare TXN & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXN | TMO |
|---|---|---|
| Founded | 1930 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.6B | 223.0B |
| IPO Year | 2002 | 1996 |
| Metric | TXN | TMO |
|---|---|---|
| Price | $281.13 | $673.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 18 |
| Target Price | $265.46 | ★ $636.00 |
| AVG Volume (30 Days) | ★ 4.8M | 1.9M |
| Earning Date | 04-22-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.11% | 0.40% |
| EPS Growth | 4.81 | ★ 7.32 |
| EPS | 3.82 | ★ 9.10 |
| Revenue | $17,682,000,000.00 | ★ $20,918,000,000.00 |
| Revenue This Year | $11.74 | $6.55 |
| Revenue Next Year | $10.43 | $5.11 |
| P/E Ratio | ★ $72.86 | $74.57 |
| Revenue Growth | 13.05 | ★ 14.47 |
| 52 Week Low | $152.73 | $435.27 |
| 52 Week High | $334.03 | $682.98 |
| Indicator | TXN | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 62.28 | 70.03 |
| Support Level | $274.83 | $589.71 |
| Resistance Level | $288.91 | N/A |
| Average True Range (ATR) | 7.47 | 15.00 |
| MACD | 2.69 | 2.63 |
| Stochastic Oscillator | 88.83 | 89.43 |
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).